Autologous stem cell transplantation in patients who object to a blood transfusion: contribution of new pharmacological haematopoiesis support. （打开新窗口）

Al-Nawakil C, Quarre MC, Heshmati F, Deau B, Park S, Dreyfus F, Bouscary D, Tamburini J.

来源‎: Br J Haematol 2013;161(5):738-40.

检索‎: PubMed 23480574

DOI码‎: 10.1111/bjh.12284

https://www.ncbi.nlm.nih.gov/pubmed/23480574 （打开新窗口）

A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. （打开新窗口）

Al-Samkari H, Parnes AD, Goodarzi K, Weitzman JI, Connors JM, Kuter DJ

来源‎: Haematologica 2021;106(4):1148-57.

检索‎: PubMed 32499239

DOI码‎: 10.3324/haematol.2020.251900

https://www.ncbi.nlm.nih.gov/pubmed/32499239 （打开新窗口）

The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. （打开新窗口）

Aribi A, Kantarjian H, Koller C, Thomas D, Faderl S, Garcia-Manero G, Cortes J.

来源‎: Cancer 2008;113(6):1338-43.

检索‎: PubMed 18629842

DOI码‎: 10.1002/cncr.23718

https://www.ncbi.nlm.nih.gov/pubmed/18629842 （打开新窗口）

Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia. （打开新窗口）

Berthelot-Richer M, Boilard B, Morin A, Bolduc B, Beauregard P, Kotb R.

来源‎: Transfusion 2012;52(4):739-41.

检索‎: PubMed 22082044

DOI码‎: 10.1111/j.1537-2995.2011.03382.x

https://www.ncbi.nlm.nih.gov/pubmed/22082044 （打开新窗口）

The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes. （打开新窗口）

Bhatia M, Davenport V, Cairo MS.

来源‎: Leuk Lymphoma 2007;48(1):9-15.

检索‎: PubMed 17325843

DOI码‎: 10.1080/10428190600909115

https://www.ncbi.nlm.nih.gov/pubmed/17325843 （打开新窗口）

Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. （打开新窗口）

Chawla SP, Staddon A, Hendifar A, Messam CA, Patwardhan R, Kamel YM.

来源‎: BMC Cancer 2013;13:121.

检索‎: PubMed 23497336

DOI码‎: 10.1186/1471-2407-13-121

https://www.ncbi.nlm.nih.gov/pubmed/23497336 （打开新窗口）

Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma. （打开新窗口）

Demeter J, Istenes I, Fodor A, Paksi M, Dombi P, Valasinyószki E, Csomor J, Matolcsy A, Nagy ZG.

来源‎: Pathol Oncol Res 2011;17(1):141-3.

检索‎: PubMed 20628840

DOI码‎: 10.1007/s12253-010-9276-4

https://www.ncbi.nlm.nih.gov/pubmed/20628840 （打开新窗口）

Eltrombopag for radiation-induced thrombocytopenia in a glioblastoma patient. （打开新窗口）

Duic JP, Grewal J, McConie K, Staszewski H, Haas J, Kesari S.

来源‎: J Neurooncol 2012;106(2):427-9.

检索‎: PubMed 21833801

DOI码‎: 10.1007/s11060-011-0675-5

https://www.ncbi.nlm.nih.gov/pubmed/21833801 （打开新窗口）

Recombinant human interleukin 11 and bacterial infection in patients with haematological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial. （打开新窗口）

Ellis M, Zwaan F, Hedström U, Poynton C, Kristensen J, Jumaa P, Wassell J, al-Ramadi B.

来源‎: Lancet 2003;361(9354):275-80.

检索‎: PubMed 12559860

https://www.ncbi.nlm.nih.gov/pubmed/12559860 （打开新窗口）

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. （打开新窗口）

Ford PA, Grant SJ, Mick R, Keck G.

来源‎: J Clin Oncol 2015;33(15):1674-9.

检索‎: PubMed 25870085

DOI码‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 （打开新窗口）

Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors. （打开新窗口）

Gao Y, Liu Q, Shen Y, Li Y, Shao K, Ye B, Shen Y, Zhou Y, Wu D

来源‎: Platelets. 2022 3;33(7):1024-1030.

检索‎: PubMed 35040375

DOI码‎: 10.1080/09537104.2022.2026910

https://pubmed.ncbi.nlm.nih.gov/35040375/ （打开新窗口）

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. （打开新窗口）

Giagounidis A, Mufti GJ, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Hu K, Woodard P, Yang AS, Kantarjian HM.

来源‎: Cancer 2014;120(12):1838-46.

检索‎: PubMed 24706489

DOI码‎: 10.1002/cncr.28663

https://www.ncbi.nlm.nih.gov/pubmed/24706489 （打开新窗口）

A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. （打开新窗口）

Greenberg PL, Garcia-Manero G, Moore M, Damon L, Roboz G, Hu K, Yang AS, Franklin J.

来源‎: Leuk Lymphoma 2013;54(2):321-8.

检索‎: PubMed 22906162

DOI码‎: 10.3109/10428194.2012.713477

https://www.ncbi.nlm.nih.gov/pubmed/22906162 （打开新窗口）

Thrombopoietin-receptor agonists in haematological disorders: the Danish experience. （打开新窗口）

Gudbrandsdottir S, Frederiksen H, Hasselbalch H.

来源‎: Platelets 2012;23(6):423-9.

检索‎: PubMed 22185370

DOI码‎: 10.3109/09537104.2011.634931

https://www.ncbi.nlm.nih.gov/pubmed/22185370 （打开新窗口）

Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial. （打开新窗口）

Han TT, Xu LP, Liu DH, Liu KY, Wang FR, Wang Y, Yan CH, Chen YH, Sun YQ, Ji Y, Wang JZ, Zhang XH, Huang XJ.

来源‎: Ann Hematol 2015;94(1):117-28.

检索‎: PubMed 25069650

DOI码‎: 10.1007/s00277-014-2158-1

https://www.ncbi.nlm.nih.gov/pubmed/25069650 （打开新窗口）

The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma. （打开新窗口）

Jeong JY, Levine MS, Abayasekara N, Berliner N, Laubach J, Vanasse GJ.

来源‎: J Hematol Oncol 2015;8:37.

检索‎: PubMed 25886818

DOI码‎: 10.1186/s13045-015-0136-2

https://www.ncbi.nlm.nih.gov/pubmed/25886818 （打开新窗口）

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. （打开新窗口）

Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P, Shammo J, Siegel R, Hu K, Franklin J, Berger DP.

来源‎: J Clin Oncol 2010;28(3):437-44.

检索‎: PubMed 20008626

DOI码‎: 10.1200/JCO.2009.24.7999

https://www.ncbi.nlm.nih.gov/pubmed/20008626 （打开新窗口）

The use of simple patient blood management strategies as an alternative to platelet and red cell transfusion in autologous stem cell transplant. （打开新窗口）

Locantore-Ford P, Grant SJ, Keck G.

来源‎: Blood 2013;122(21):2140.

https://www.bloodjournal.org/content/122/21/2140 （打开新窗口）

The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply. （打开新窗口）

Loo M, Beguin Y.

来源‎: Blood 1999;93(10):3286-93.

检索‎: PubMed 10233880

https://www.ncbi.nlm.nih.gov/pubmed/10233880 （打开新窗口）

A single center experience with romiplostim for the management of chemotherapy-induced thrombocytopenia. （打开新窗口）

Miao J, Leblebjian H, Scullion B, Parnes A

来源‎: Am J Hematol 2018;93(4):E86-E88.

检索‎: PubMed 29274130

DOI码‎: 10.1002/ajh.25022

https://www.ncbi.nlm.nih.gov/pubmed/29274130 （打开新窗口）

Pharmacological therapies to minimise platelet transfusion. （打开新窗口）

Norfolk DR, Seghatchian J.

来源‎: Transfus Sci 2000;22(3):149-53.

检索‎: PubMed 10831916

https://www.ncbi.nlm.nih.gov/pubmed/10831916 （打开新窗口）

Romiplostim for management of chemotherapy-induced thrombocytopenia. （打开新窗口）

Parameswaran R, Lunning M, Mantha S, Devlin S, Hamilton A, Schwartz G, Soff G.

来源‎: Support Care Cancer 2014;22(5):1217-22.

检索‎: PubMed 24414994

DOI码‎: 10.1007/s00520-013-2074-2

https://www.ncbi.nlm.nih.gov/pubmed/24414994 （打开新窗口）

Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders. （打开新窗口）

Pathak S, Roth M, Verma A, Steidl U.

来源‎: Expert Opin Drug Metab Toxicol 2013;9(12):1667-75.

检索‎: PubMed 24215532

DOI码‎: 10.1517/17425255.2013.858119

https://www.ncbi.nlm.nih.gov/pubmed/24215532 （打开新窗口）

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. （打开新窗口）

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

来源‎: Leuk Lymphoma. 2019;60(9):2324-7.

检索‎: PubMed 30773115

DOI码‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 （打开新窗口）

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. （打开新窗口）

Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A.

来源‎: Lancet Haematol 2015;2(10):e417-26.

检索‎: PubMed 26686043

https://www.ncbi.nlm.nih.gov/pubmed/26686043 （打开新窗口）

Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation. （打开新窗口）

Poon LM, Di Stasi A, Popat U, Champlin RE, Ciurea SO.

来源‎: Am J Blood Res 2013;3(3):260-4.

检索‎: PubMed 23997988

https://www.ncbi.nlm.nih.gov/pubmed/23997988 （打开新窗口）

Safety and efficacy of eltrombopag in post-hematopoietic stem cell transplantation (HSCT) thrombocytopenia. （打开新窗口）

Raut SS, Shah SA, Sharanangat VV, Shah KM, Patel KA, Anand AS, Talati SS, Panchal HP, Patel AA, Parikh SK, Shukla SN.

来源‎: Indian J Hematol Blood Transfus 2015;31(4):413-5.

检索‎: PubMed 26306064

DOI码‎: 10.1007/s12288-014-0491-0

https://www.ncbi.nlm.nih.gov/pubmed/26306064 （打开新窗口）

Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. （打开新窗口）

Reese JA, Li X, Hauben M, Aster RH, Bougie DW, Curtis BR, George JN, Vesely SK.

来源‎: Blood 2010;116(12):2127-33.

检索‎: PubMed 20530792

DOI码‎: 10.1182/blood-2010-03-276691

https://www.ncbi.nlm.nih.gov/pubmed/20530792 （打开新窗口）

Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. （打开新窗口）

Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U.

来源‎: Blood 2012;120(2):386-94.

检索‎: PubMed 22627766

DOI码‎: 10.1182/blood-2011-12-399667

https://www.ncbi.nlm.nih.gov/pubmed/22627766 （打开新窗口）

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. （打开新窗口）

Sekeres MA, Kantarjian H, Fenaux P, Becker P, Boruchov A, Guerci-Bresler A, Hu K, Franklin J, Wang YM, Berger D.

来源‎: Cancer 2011;117(5):992-1000.

检索‎: PubMed 20945323

DOI码‎: 10.1002/cncr.25545

https://www.ncbi.nlm.nih.gov/pubmed/20945323 （打开新窗口）

Romiplostim treatment of chemotherapy-induced thrombocytopenia. （打开新窗口）

Soff GA, Miao Y, Bendheim G, Batista J, Mones JV, Parameswaran R, Wilkins CR, Devlin SM, Abou-Alfa GK, Cercek A, Kemeny NE, Sarasohn DM, Mantha S

来源‎: J Clin Oncol 2019;37(31):2892-8.

检索‎: PubMed 31545663

DOI码‎: 10.1200/JCO.18.01931

https://www.ncbi.nlm.nih.gov/pubmed/31545663 （打开新窗口）

Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. （打开新窗口）

Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, Kabrna E, Geissler K, Jilma B.

来源‎: Blood 2000;95(9):2983-9.

检索‎: PubMed 10779449

https://www.ncbi.nlm.nih.gov/pubmed/10779449 （打开新窗口）

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. （打开新窗口）

Svensson T, Chowdhury O, Garelius H, Lorenz F, Saft L, Jacobsen SE, Hellström-Lindberg E, Cherif H.

来源‎: Eur J Haematol 2014;93(5):439-45.

检索‎: PubMed 24853277

DOI码‎: 10.1111/ejh.12383

https://www.ncbi.nlm.nih.gov/pubmed/24853277 （打开新窗口）

Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation. （打开新窗口）

Tanaka T, Inamoto Y, Yamashita T, Fuji S, Okinaka K, Kurosawa S, Kim SW, Tanosaki R, Fukuda T.

来源‎: Biol Blood Marrow Transplant 2016;22(5):919-24.

检索‎: PubMed 26785333

DOI码‎: 10.1016/j.bbmt.2016.01.018

https://www.ncbi.nlm.nih.gov/pubmed/26785333 （打开新窗口）

Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. （打开新窗口）

Tsimberidou AM, Giles FJ, Khouri I, Bueso-Ramos C, Pilat S, Thomas DA, Cortes J, Kurzrock R.

来源‎: Ann Oncol 2005;16(1):139-45.

检索‎: PubMed 15598951

DOI码‎: 10.1093/annonc/mdi007

https://www.ncbi.nlm.nih.gov/pubmed/15598951 （打开新窗口）

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. （打开新窗口）

Wang ES, Lyons RM, Larson RA, Gandhi S, Liu D, Matei C, Scott B, Hu K, Yang AS.

来源‎: J Hematol Oncol 2012;5:71.

检索‎: PubMed 23190430

DOI码‎: 10.1186/1756-8722-5-71

https://www.ncbi.nlm.nih.gov/pubmed/23190430 （打开新窗口）

Romiplostim for chemotherapy-induced thrombocytopenia: efficacy and safety of extended use. （打开新窗口）

Wilkins CR, Ortiz J, Gilbert LJ, Yin S, Mones JV, Parameswaran R, Mantha S, Soff GA

来源‎: Res Pract Thromb Haemost. 2022;6(3):e12701.

检索‎: PubMed 35582038

DOI码‎: 10.1002/rth2.12701

https://pubmed.ncbi.nlm.nih.gov/35582038/ （打开新窗口）

Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. （打开新窗口）

Will B, Kawahara M, Luciano JP, Bruns I, Parekh S, Erickson-Miller CL, Aivado MA, Verma A, Steidl U.

来源‎: Blood 2009;114(18):3899-908.

检索‎: PubMed 19710504

DOI码‎: 10.1182/blood-2009-04-219493

https://www.ncbi.nlm.nih.gov/pubmed/19710504 （打开新窗口）